Human immunodeficiency virus type 1 clade AE antigens (HIV-1 CRF01_AE antigens)

Human immunodeficiency virus type 1 (HIV-1) clade AE antigens refer to the specific viral proteins derived from the CRF01_AE recombinant form, which is the predominant HIV-1 strain in Southeast Asia (Hemelaar et al., 2011, AIDS). These antigens, most notably the envelope glycoprotein gp120 and the Gag and Pro proteins, are utilized in vaccine strategies to prime and boost the host immune system rather than serving as targets for direct enzymatic inhibition by small molecules (Rerks-Ngarm et al., 2009, NEJM). In the landmark RV144 clinical trial, a combination of a canarypox vector (ALVAC-HIV) and a recombinant gp120 protein (AIDSVAX B/E) containing these antigens demonstrated a modest 31.2% efficacy in preventing HIV-1 infection (Haynes et al., 2012, NEJM). The biological role of these antigens in the viral life cycle includes mediating attachment to host CD4 receptors and facilitating membrane fusion. In a therapeutic context, they are designed to elicit V1V2-specific antibodies, which have been identified as a primary correlate of reduced infection risk in vaccinated populations (Robb et al., 2012, The Lancet). Because the virus undergoes rapid antigenic drift, these antigens must be carefully selected to match circulating regional strains to ensure maximum immunological recognition.

Other names

HIV-1 subtype AE antigensCRF01_AE proteinsRV144 vaccine antigensALVAC-HIV (vCP1521) antigensAIDSVAX B/E antigens

Induction of humoral and cellular immune responses, specifically the production of V1V2-directed non-neutralizing antibodies and CD4+ T-cell activation to prevent viral acquisition.